

VALUE-BASED CONTRACTS: 2009 – Q4 2019

This list includes value-based contracts (VBC) executed and publicly announced in the United States from 2009-2019. This list includes public program VBCs to the extent that they are modeled similarly to commercial contracts, but does not include other public program contracts that may be seen as types of VBCs (e.g., Coverage with Evidence Development). This list is not comprehensive; we believe many VBCs are executed without the release of publicly available information. New information will be added as it becomes available.

This list is current as of February 2020.

	Brand Name	Non-Proprietary Name	Year	Therapeutic Area	Condition	Biopharmaceutical Company	Payer
1	Unknown	-	2019	Oncology	Cancer	Pfizer	Prime Therapeutics
2	Stiolto	tiotropium bromide/ olodaterol	2019	Respiratory	Chronic Obstructive Pulmonary Disease	Boehringer Ingelheim	Highmark
3	Enbrel	etanercept	2019	Immunology	Rheumatoid arthritis	Amgen	Abarca
4	Givlaari	givosiran	2019	Neurology	Acute hepatic porphyria	Alnylam Pharmaceuticals	Harvard Pilgrim Health Care
5	Tecfidera	dimethyl fumarate	2019	Neurology	Multiple Sclerosis	Biogen	UPMC Health Plan
6	Avonex	interferon beta-1a	2019	Neurology	Multiple Sclerosis	Biogen	UPMC Health Plan
7	Luxturna	voretigene neparvovec- rzyl	2019	Ophthalmology	Retinal Dystrophy	Spark Therapeutics	Cigna
8	Eplclusa	sofosbuvir/velpatasvir	2019	Infectious Disease	Hepatitis C	Gilead (Asegua Therapeutics)	Louisiana Department of Health
9	Zolgensma	onasemnogene abeparvovec-xioi	2019	Neurology	Spinal muscular atrophy	Novartis (Avexis)	Cigna
10	Zolgensma	onasemnogene abeparvovec-xioi	2019	Neurology	Spinal muscular atrophy	Novartis (Avexis)	Harvard Pilgrim Health Care
11	Mavyret	glecaprevir/pibrentasvir	2019	Infectious Disease	Hepatitis C	AbbVie	Washington State Health Care Authority
12	Brilinta	ticagrelor	2019	Cardiology	Acute Coronary Events	AstraZeneca	UPMC Health Plan
13	Invega Trinza / Invega Sustenna	paliperidone palmitate	2018	Mental Health	Schizophrenia	Janssen	Oklahoma Health Care Authority
14	Fycompa	perampanel	2018	Neurology	Epilepsy	Eisai	Oklahoma Health Care Authority
15	Stelara	ustekinumab	2018	Immunology	Psoriasis	Janssen	Prime Therapeutics
16	Jardiance	empagliflozin	2018	Endocrinology	Diabetes	Boehringer Ingelheim	UPMC Health Plan
17	Orbativ	oritavancin	2018	Infectious Disease	Acute Bacterial Skin Infections	Melinta Therapeutics	Oklahoma Health Care Authority
18	Aristada	aripiprazole lauroxil	2018	Mental Health	Schizophrenia	Alkermes	Oklahoma Health Care Authority
19	Vivitrol	naltrexone	2018	Neurology	Opioid Dependence	Alkermes	UPMC Health Plan
20	Cosentyx	secukinumab	2018	Immunology	Psoriasis	Novartis	Prime Therapeutics
21	Onpatro	patisiran	2018	Endocrinology	Polyneuropathy of Hereditary ATTR (hATTR) Amyloidosis	Alnylam Pharmaceuticals	Harvard Pilgrim Health Care

VALUE-BASED CONTRACTS: 2009 – Q4 2019

This list includes value-based contracts (VBC) executed and publicly announced in the United States from 2009-2019. This list includes public program VBCs to the extent that they are modeled similarly to commercial contracts, but does not include other public program contracts that may be seen as types of VBCs (e.g., Coverage with Evidence Development). This list is not comprehensive; we believe many VBCs are executed without the release of publicly available information. New information will be added as it becomes available.

This list is current as of February 2020.

22	Jardiance	empagliflozin	2018	Endocrinology	Diabetes	Boehringer Ingelheim	Highmark
23	Praluent	alirocumab	2018	Cardiology	Hypercholesterolemia	Sanofi, Regeneron	Express Scripts
24	Symbicort	budesonide/formoterol fumarate dihydrate	2018	Respiratory	Asthma	AstraZeneca	Harvard Pilgrim Health Care
25	Symbicort	budesonide/formoterol fumarate dihydrate	2018	Respiratory	Asthma, Chronic Obstructive Pulmonary Disease	AstraZeneca	Highmark
26	Victoza	liraglutide	2018	Endocrinology	Diabetes	Novo Nordisk	SelectHealth
27	Repatha	evolocumab	2018	Cardiology	Hypercholesterolemia	Amgen	Abarca
28	Jardiance	empagliflozin	2018	Endocrinology	Diabetes	Boehringer Ingelheim	Prime Therapeutics
29	Luxturna	voretigene neparvovec-rzyl	2018	Ophthalmology	Retinal Dystrophy	Spark Therapeutics	Harvard Pilgrim Health Care
30	Luxturna	voretigene neparvovec	2018	Ophthalmology	Retinal dystrophy	Spark Therapeutics	Express Scripts
31	Aimovig	erenumab-aooe	2018	Neurology	Migraine	Amgen / Novartis	Express Scripts
32	MS Portfolio	-	2017	Neurology	Multiple Sclerosis	Biogen	Prime Therapeutics
33	Victoza	liraglutide	2017	Endocrinology	Diabetes	Novo Nordisk	Prime Therapeutics
34	Xtampza ER	oxycodone	2017	Addiction	Pain management	Collegium	Cigna
35	Unspecified	-	2017	Neurology	Multiple Sclerosis	Unspecified	Express Scripts
36	Unspecified	-	2017	Neurology	Multiple Sclerosis	Biogen	Harvard Pilgrim Health Care
37	Unspecified	-	2017	Neurology	Multiple Sclerosis	Biogen	Moda Health
38	Unspecified	-	2017	Neurology	Multiple Sclerosis	Biogen	SelectHealth
39	Unspecified	-	2017	Neurology	Multiple Sclerosis	Biogen	Abarca
40	Brilinta	ticagrelor	2017	Cardiology	Acute Coronary Events	AstraZeneca	Harvard Pilgrim Health Care
41	Bydureon	exenatide	2017	Endocrinology	Diabetes	AstraZeneca	Harvard Pilgrim Health Care
42	Repatha	evolocumab	2017	Cardiology	Hypercholesterolemia	Amgen	Harvard Pilgrim Health Care
43	Enbrel	etanercept	2017	Immunology	Rheumatoid arthritis	Amgen	Harvard Pilgrim Health Care
44	Forteo	teripararide	2017	Musculoskeletal	Osteoporosis	Eli Lilly	Harvard Pilgrim Health Care
45	Victoza	liraglutide	2017	Endocrinology	Diabetes	Novo Nordisk	Humana
46	Janumet/Januvia	metformin/sitagliptin, sitagliptin	2016	Endocrinology	Diabetes	Merck	Aetna
47	Entresto	sacubitril/valsartan	2016	Cardiology	Chronic Heart Failure	Novartis	Harvard Pilgrim Health Care
48	Trulicity	dulaglutide	2016	Endocrinology	Diabetes	Eli Lilly	Harvard Pilgrim Health Care

VALUE-BASED CONTRACTS: 2009 – Q4 2019

This list includes value-based contracts (VBC) executed and publicly announced in the United States from 2009-2019. This list includes public program VBCs to the extent that they are modeled similarly to commercial contracts, but does not include other public program contracts that may be seen as types of VBCs (e.g., Coverage with Evidence Development). This list is not comprehensive; we believe many VBCs are executed without the release of publicly available information. New information will be added as it becomes available.

This list is current as of February 2020.

49	Brilinta	ticagrelor	2016	Cardiology	Acute Coronary Events	AstraZeneca	UPMC Health Plan
50	Iressa	gefitinib	2016	Oncology	Lung Cancer	AstraZeneca	Express Scripts
51	Praluent	alirocumab	2016	Cardiology	Hypercholesterolemia	Sanofi, Regeneron	Cigna
52	Repatha	evolocumab	2016	Cardiology	Hypercholesterolemia	Amgen	Cigna
53	Effient	prasugrel	2016	Cardiology	Acute Coronary Events	Eli Lilly	Humana
54	Entresto	sacubitril/valsartan	2016	Cardiology	Chronic Heart Failure	Novartis	Cigna
55	Entresto	sacubitril/valsartan	2016	Cardiology	Chronic Heart Failure	Novartis	Aetna
56	Praluent	alirocumab	2015	Cardiology	Hypercholesterolemia	Sanofi, Regeneron	Prime Therapeutics
57	Repatha	evolocumab	2015	Cardiology	Hypercholesterolemia	Amgen	Prime Therapeutics
58	Repatha	evolocumab	2015	Cardiology	Hypercholesterolemia	Amgen	CVS Health
59	Repatha	evolocumab	2015	Cardiology	Hypercholesterolemia	Amgen	Harvard Pilgrim Health Care
60	Tarceva	erlotinib	2015	Oncology	Pancreatic Cancer, Lung Cancer	Genentech	Express Scripts
61	Harvoni	ledispavir/sofosbuvir	2015	Infectious Disease	Hepatitis C	Gilead	Cigna
62	Harvoni/Sovaldi	ledispavir/sofosbuvir, sofosbuvir	2015	Infectious Disease	Hepatitis C	Gilead	Catamaran
63	Avastin	bevacizumab	2015	Oncology	Lung Cancer	Genentech	Priority Health
64	Crestor	rosuvastatin	2014	Cardiology	High Cholesterol	AstraZeneca	Cigna
65	Viekira Pak	ombitasvir/paritaprevir/ritonavir and dasabuvir	2014	Infectious Disease	Hepatitis C	AbbVie	Express Scripts
66	Rebif	interferon beta-1a	2012	Neurology	Multiple Sclerosis	EMD Serono	Prime Therapeutics
67	Actonel	risedronate sodium	2011	Musculoskeletal	Osteoporosis	Warner Chilcott	Prime Therapeutics
68	Ampyra	dalfampridine	2011	Neurology	Multiple Sclerosis	Acordia	Unspecified
69	Betaseron	interferon beta-1b	2011	Neurology	Multiple Sclerosis	Bayer	Health Alliance Medical Plans
70	Januvia	sitagliptin	2011	Endocrinology	Diabetes	Merck	Prime Therapeutics
71	Rebif	interferon beta-1a	2011	Neurology	Multiple Sclerosis	EMD Serono	Cigna
72	Actonel	risedronate sodium	2009	Musculoskeletal	Osteoporosis	Procter & Gamble, Sanofi-Aventis	Health Alliance Medical Plans
73	Janumet/Januvia	metformin/sitagliptin, sitagliptin	2009	Endocrinology	Diabetes	Merck	Cigna